Skip to content

Study · Animal study (in vivo) · rat · 2000

3 results

Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157.

Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Duplancic B, Marovic A, Zoricic I, Prkacin I, Lovric-Bencic M, Aralica G and 11 more

Show all authors

Ziger T, Perovic D, Jelovac N, Dodig G, Rotkvic I, Mise S, Seiwerth S, Turkovic B, Grabarevic Z, Petek M, Rucman R

Journal of physiology, Paris1 Mar 2000Cited by 20 (Europe PMC)

PMID10791690 (opens in a new tab)DOI10.1016/s0928-4257(00)00147-9 (opens in a new tab)PepBankPUB-10791690
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given haloperidol, BPC‑157 prevented gastric lesions.

    In plain wordsIn rats given haloperidol, BPC‑157 prevented stomach lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol-gastric lesions
    Study

    ratn: not reported in source

    gastric lesions from dopamine system failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Ranitidine (10 mg), omeprazole (10 mg), atropine (10 mg), pentadecapeptide BPC 157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) (10 microg or 10 ng x kg(-1) i.p.) evidently prevented both haloperidol-gastric lesions and reserpine-gastric lesions.
    1 context sentence
    Summary · context
    For this purpose, a co-administration of reserpine and haloperidol, a dopamine granule depletor combined with a dopamine antagonist with pronounced ulcerogenic effect, was tested, and the rats were sacrificed 24 h after injurious agent(s) administration.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given reserpine, BPC‑157 prevented gastric lesions.

    In plain wordsIn rats given reserpine, BPC‑157 prevented stomach lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseReserpine-gastric lesions
    Study

    ratn: not reported in source

    gastric lesions from dopamine system failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Ranitidine (10 mg), omeprazole (10 mg), atropine (10 mg), pentadecapeptide BPC 157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) (10 microg or 10 ng x kg(-1) i.p.) evidently prevented both haloperidol-gastric lesions and reserpine-gastric lesions.
    1 context sentence
    Summary · context
    For this purpose, a co-administration of reserpine and haloperidol, a dopamine granule depletor combined with a dopamine antagonist with pronounced ulcerogenic effect, was tested, and the rats were sacrificed 24 h after injurious agent(s) administration.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given haloperidol and reserpine together, which produced larger lesions, BPC‑157 kept its beneficial effect on gastric lesions.

    In plain wordsIn rats with the biggest stomach lesions from two drugs together, BPC‑157 still protected the stomach.

    Peptide
    BPC-157
    Outcome
    DecreaseGastric lesions after haloperidol plus reserpine
    Study

    ratn: not reported in source

    gastric lesions from dopamine system failure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Confronted with potentiated lesions following a combination of haloperidol and reserpine, these agents maintained their beneficial effects, noted in the rats treated with either haloperidol or reserpine alone.
    1 context sentence
    Summary · context
    For this purpose, a co-administration of reserpine and haloperidol, a dopamine granule depletor combined with a dopamine antagonist with pronounced ulcerogenic effect, was tested, and the rats were sacrificed 24 h after injurious agent(s) administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.